ALEMBIC PHARMA | AUROBINDO PHARMA | ALEMBIC PHARMA/ AUROBINDO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 17.5 | 18.5 | 94.1% | View Chart |
P/BV | x | 6.9 | 4.0 | 172.8% | View Chart |
Dividend Yield | % | 0.5 | 0.3 | 209.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-19 |
AUROBINDO PHARMA Mar-19 |
ALEMBIC PHARMA/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 664 | 830 | 80.0% | |
Low | Rs | 412 | 527 | 78.2% | |
Sales per share (Unadj.) | Rs | 208.7 | 333.9 | 62.5% | |
Earnings per share (Unadj.) | Rs | 31.0 | 40.4 | 76.8% | |
Cash flow per share (Unadj.) | Rs | 37.1 | 51.8 | 71.7% | |
Dividends per share (Unadj.) | Rs | 5.50 | 2.50 | 220.0% | |
Dividend yield (eoy) | % | 1.0 | 0.4 | 277.4% | |
Book value per share (Unadj.) | Rs | 144.2 | 237.1 | 60.8% | |
Shares outstanding (eoy) | m | 188.52 | 585.91 | 32.2% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 2.6 | 2.0 | 126.9% | |
Avg P/E ratio | x | 17.4 | 16.8 | 103.3% | |
P/CF ratio (eoy) | x | 14.5 | 13.1 | 110.6% | |
Price / Book Value ratio | x | 3.7 | 2.9 | 130.4% | |
Dividend payout | % | 17.7 | 6.2 | 286.4% | |
Avg Mkt Cap | Rs m | 101,461 | 397,569 | 25.5% | |
No. of employees | `000 | NA | 17.9 | 0.0% | |
Total wages/salary | Rs m | 7,467 | 25,849 | 28.9% | |
Avg. sales/employee | Rs Th | NM | 10,956.9 | - | |
Avg. wages/employee | Rs Th | NM | 1,447.7 | - | |
Avg. net profit/employee | Rs Th | NM | 1,324.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,347 | 195,636 | 20.1% | |
Other income | Rs m | 94 | 1,553 | 6.0% | |
Total revenues | Rs m | 39,441 | 197,189 | 20.0% | |
Gross profit | Rs m | 8,736 | 39,519 | 22.1% | |
Depreciation | Rs m | 1,152 | 6,680 | 17.3% | |
Interest | Rs m | 184 | 2,626 | 7.0% | |
Profit before tax | Rs m | 7,493 | 31,767 | 23.6% | |
Minority Interest | Rs m | 11 | 27 | 40.0% | |
Prior Period Items | Rs m | -93 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -881 | 0.0% | |
Tax | Rs m | 1,568 | 7,269 | 21.6% | |
Profit after tax | Rs m | 5,844 | 23,645 | 24.7% | |
Gross profit margin | % | 22.2 | 20.2 | 109.9% | |
Effective tax rate | % | 20.9 | 22.9 | 91.4% | |
Net profit margin | % | 14.9 | 12.1 | 122.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,577 | 153,645 | 12.7% | |
Current liabilities | Rs m | 14,896 | 120,429 | 12.4% | |
Net working cap to sales | % | 11.9 | 17.0 | 70.1% | |
Current ratio | x | 1.3 | 1.3 | 103.0% | |
Inventory Days | Days | 90 | 135 | 66.4% | |
Debtors Days | Days | 45 | 64 | 71.2% | |
Net fixed assets | Rs m | 27,097 | 103,909 | 26.1% | |
Share capital | Rs m | 377 | 586 | 64.3% | |
"Free" reserves | Rs m | 26,811 | 138,322 | 19.4% | |
Net worth | Rs m | 27,188 | 138,908 | 19.6% | |
Long term debt | Rs m | 4,993 | 1,800 | 277.5% | |
Total assets | Rs m | 47,778 | 264,544 | 18.1% | |
Interest coverage | x | 41.7 | 13.1 | 318.4% | |
Debt to equity ratio | x | 0.2 | 0 | 1,417.6% | |
Sales to assets ratio | x | 0.8 | 0.7 | 111.4% | |
Return on assets | % | 12.6 | 9.9 | 127.0% | |
Return on equity | % | 21.5 | 17.0 | 126.3% | |
Return on capital | % | 23.6 | 23.8 | 99.0% | |
Exports to sales | % | 0 | 49.6 | 0.0% | |
Imports to sales | % | 0 | 18.8 | 0.0% | |
Exports (fob) | Rs m | NA | 97,091 | 0.0% | |
Imports (cif) | Rs m | NA | 36,741 | 0.0% | |
Fx inflow | Rs m | 19,453 | 97,316 | 20.0% | |
Fx outflow | Rs m | 6,065 | 40,589 | 14.9% | |
Net fx | Rs m | 13,388 | 56,727 | 23.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,120 | 16,220 | 50.1% | |
From Investments | Rs m | -7,556 | -28,768 | 26.3% | |
From Financial Activity | Rs m | 590 | 19,191 | 3.1% | |
Net Cashflow | Rs m | 1,153 | 6,656 | 17.3% |
Indian Promoters | % | 74.1 | 54.1 | 137.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.9 | 8.0 | 36.5% | |
FIIs | % | 9.1 | 27.7 | 32.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 13.9 | 10.2 | 136.3% | |
Shareholders | 49,328 | 69,601 | 70.9% | ||
Pledged promoter(s) holding | % | 0.0 | 8.6 | - |
Compare ALEMBIC PHARMA With: FDC UNICHEM LAB DR. REDDYS LAB AJANTA PHARMA ALEMBIC
Compare ALEMBIC PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More